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ABSTRACT
Background: Substantial amounts of public funds are
invested in health research worldwide. Publicly funded
randomised controlled trials (RCTs) often recruit
participants at a slower than anticipated rate. Many
trials fail to reach their planned sample size within the
envisaged trial timescale and trial funding envelope.
Objectives: To review the consent, recruitment and
retention rates for single and multicentre randomised
control trials funded and published by the UK’s
National Institute for Health Research (NIHR) Health
Technology Assessment (HTA) Programme.
Data sources and study selection: HTA reports of
individually randomised single or multicentre RCTs
published from the start of 2004 to the end of April
2016 were reviewed.
Data extraction: Information was extracted, relating
to the trial characteristics, sample size, recruitment and
retention by two independent reviewers.
Main outcome measures: Target sample size and
whether it was achieved; recruitment rates (number of
participants recruited per centre per month) and
retention rates (randomised participants retained and
assessed with valid primary outcome data).
Results: This review identified 151 individually RCTs
from 787 NIHR HTA reports. The final recruitment
target sample size was achieved in 56% (85/151) of
the RCTs and more than 80% of the final target
sample size was achieved for 79% of the RCTs (119/
151). The median recruitment rate (participants per
centre per month) was found to be 0.92 (IQR 0.43–
2.79) and the median retention rate (proportion of
participants with valid primary outcome data at follow-
up) was estimated at 89% (IQR 79–97%).
Conclusions: There is considerable variation in the
consent, recruitment and retention rates in publicly
funded RCTs. Investigators should bear this in mind at
the planning stage of their study and not be overly
optimistic about their recruitment projections.
INTRODUCTION
Substantial amounts of public funds are
invested in medical research worldwide with
an estimate of US$100 billion in 2012.1 In
2014/2015, the National Institute for Health
Research (NIHR) in England spent £237.6
million across a broad range of research pro-
grammes and initiatives to ensure that
Strengths and limitations of this study
▪ Substantial amounts of public funds are spent
on healthcare research and randomised con-
trolled trials (RCTs) and this is potentially
wasted if a trial fails to recruit to time and target
sample size. Trialists and funders have high-
lighted recruitment and retention as a key issue
for the conduct of RCTs.
▪ This study reports the recruitment and retention
rates for 151 single and multicentre randomised
control trials funded by the UK’s National
Institute for Health Research (NIHR) Health
Technology Assessment (HTA) Programme and
published in the HTA Journal between 2004 and
2016.
▪ There is considerable variation in the consent,
recruitment and retention rates in publicly
funded RCTs.
▪ Crude recruitment rates, assuming all centres
were recruiting for the same time period were
calculated; as such the recruitment rate estimates
may be an underestimation of the true recruit-
ment rate. The study was restricted to publicly
funded RCTs published as reports in the HTA
Journal and not commercially sponsored trials.
▪ Recruitment to trials is complex and the com-
plete picture cannot be untangled in a simple
review.
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patients and the public beneﬁt from the most cost-
effective, up-to-date health interventions and treat-
ments.2 A substantial proportion of this research
expenditure was invested in Randomised Controlled
Trials (RCTs) to assess the clinical and cost-effectiveness
of new health technologies. RCTs are widely regarded as
the most powerful research design for evaluating new
health technologies and decision makers, such as the
UK’s National Institute for Health and Care Excellence
(NICE), are increasingly using the results of RCTs to
guide practice and policy.
A frequently reported problem with publicly funded
RCTs is that the recruitment of participants is often
slower or more difﬁcult than expected. Many trials fail
to reach their planned sample size within the originally
envisaged trial timescale and trial funding envelope. A
review of a cohort of 122 trials funded by the UK
Medical Research Council (MRC) and the NIHR Health
Technology Assessment Programme (HTA), between
1994 and 2002 found that less than a third (31%) of the
trials achieved their original patient recruitment target;
55/122 (45.1%) achieved < 80% of their original target
and half (53%) were awarded an extension.3 This situ-
ation has improved marginally over time, with a recent
review of 73 HTA/MRC funded studies recruiting
between 2002 and 2008,4 ﬁnding that 55% (40/73) of
the trials achieved their original patient recruitment
target; 16/73 (22%) achieved <80% of their original
target and 45% (33/73) were awarded an extension.4
A HTA commissioned review recommended further
research is required, particularly in relation to: problems
being experienced and solutions employed in current
RCTs; the optimum structure, stafﬁng and organisation
for the conduct of large and small trials; and the factors
which inﬂuence the participation5 in RCTs. Several
Cochrane systematic reviews have suggested strategies to
improve the recruitment6 7 and retention8 of partici-
pants to RCTs. These recruitment strategies include:
telephone reminders; requiring potential participants to
opt-out of being contacted by the trial team regarding
participation; and open (unblinded) designs. Other
HTA commissioned reviews have shown that participant
and clinician preferences, for the intervention, can
affect trial recruitment9 and that payment to healthcare
professionals for patient recruitment to trials acts as a
limited incentive.10 However despite the growing litera-
ture summarising the barriers and facilitators to recruit-
ment to RCTs only 55% of trials are recruiting to within
80% of the target. A recent survey among the directors
of the clinical trials units registered with the UK NIHR
Clinical Research Network identiﬁed priorities for
research into the methodology of trials. The top three
priorities were improving recruitment, choice of out-
comes and improving retention.11
The Consolidated Standards of Reporting Trials
(CONSORT) Statement, ﬁrst published in 1996,12 13 and
revised in 200114 and 2010,15 is a set of standards for pub-
lication of results of RCTS in medical journals. They are
for the article itself and the article abstract.15 The
CONSORT statement includes details of the number of
eligible patients; number of patients randomised; number
of recruiting centres and recruitment time period (start
and ﬁnish time of recruitment). A review of publicly
funded RCTs was carried out to evaluate how well recruit-
ment and retention ﬁgures are reported; how successful
RCTs are in reaching their target sample size and retain-
ing participants and to assess recruitment rates.
METHODS
Trial identification
Reports of individually RCTs published in the NIHR HTA
Journal from January 2004 to April 2016 were reviewed.
The HTA Journal publishes research on the effectiveness,
costs and broader impact of health technologies for those
who use, manage and provide care in the NHS. Reports
are published in the HTA Journal if (1) they have resulted
from work for the NIHR HTA Programme and (2) they
are of a sufﬁciently high scientiﬁc quality as assessed by
the external reviewers and journal editors (http://www.
journalslibrary.nihr.ac.uk/hta/about-the-journal). Trial
reports published in the HTA Journal were chosen as they
are of high quality and provide detailed trial and recruit-
ment information including the number of centres and
recruitment period.
A pilot review of 30 trials reported in ﬁve major jour-
nals: British Medical Journal (BMJ), The Lancet, New
England Journal of Medicine, The Journal of the
American Medical Association ( JAMA) and Annals of
Internal Medicine as well as six trials reported in the
HTA Journal, found that there was sufﬁcient information
to calculate the recruitment rate for only 23 out of the
30 trials reported in the journals. This information was
available for all six trials reported in the HTA Journal.
The pilot identiﬁed six trials published in the HTA
journal over a 7 months period and with a basic extrapo-
lation over a 12 year publication period it was deemed
this would provide a large and manageable number of
trials for review. Limiting the review to publicly funded
trials published in the HTA Journal identiﬁed trials from
medicine, surgery and therapy as well as from a range of
disease areas.
The HTA Journal reports were obtained from the
NIHR Journals Library website (http://www.
journalslibrary.nihr.ac.uk/hta—date last accessed 10
August 2016) along with any previously published trial
paper, protocol paper or trial protocol, where available.
For trials that had a published International
Standardised Randomised Controlled Trial Number
(ISRCTN) number this was used to check the ISRCTN
register of clinical trials for any additional information, a
trial website or any previously unobtainable trial reports
(cf. http://www.isrctn.com/). The trial report published
in the HTA Journal was used as the main resource where
there were discrepancies in reporting. The titles and
abstracts of all reports published in the HTA journal
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from January 2004 to April 2016 were checked for rele-
vance. January 2004 was chosen as a start date for the
review because there were relatively few reports of RCTs
in the ﬁrst 7 years of the HTA Journal from 1997 to 2003
(13 RCTs out of 208 reports).
Inclusion/exclusion criteria
Trials included in the review were single and multicentre
RCTs that were either fully or partially randomised and
recruitment to the trial had ﬁnished. Where trials had
reported early termination, either prior to completion
of recruitment or following recruitment but prior to
completion of follow-up, the trials were retained in the
review and the reason for the termination was noted.
Trials that were nested parallel trials as part of another
RCT were included as were trial reports of two or more
parallel RCTs. Trials that were excluded include: cluster
randomised trials as these have separate speciﬁc recruit-
ment issues;16 adaptive designs and pilot trials. HTA
reports of a pilot trial that went on to a full trial were
retained and the results from the full trial were extracted
and included in the review. Trials of inﬂuenza vaccin-
ation were excluded as these recruit patients over a short
period of time, usually 1–3 months, and so have an
exceptionally high recruitment rate.
Data extraction
Once HTA reports had been selected for inclusion,
information was extracted, using a standardised data
extraction form. For each trial the following general trial
information was extracted: the trial design, the clinical
area, use of blinding, intervention type, type of control,
number of arms, single or multicentre and number of
centres, recruitment setting and the number and timing
of follow-up visits. Data relating to the sample size and
recruitment rate was extracted including: the target and
actual sample size, the overall and centre-speciﬁc recruit-
ment period and CONSORT information on the
numbers screened, consented, randomised and analysed
with the primary outcome.17 Where available more
detailed trial information was recorded including: use of
a pilot, whether there was support from a trials unit, geo-
graphical region, recruitment strategy and country
where the trial took place. Data extraction was carried
out by a team of reviewers. Each article was independ-
ently reviewed by a second member of the review team.
Any uncertainties were resolved by discussion.
The standard of reporting of trial information was
good but for some variables the details were not always
available. There was limited information about whether
trials had any form of pilot phase or had involvement
from a clinical trials unit. These features were recorded
as absent where they were not mentioned.
The primary outcome for the review was considered to
be the recruitment rate for each trial. To calculate this
accurately the centre-speciﬁc recruitment periods within
the trials were extracted. However, this was generally
poorly reported.
Figure 1 Flow diagram of
search process for a review of
trial reports published in the
Health Technology Assessment
Journal between 2004 and end of
April 2016. RCT, randomised
controlled trials.
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Analysis
The recruitment rate was deﬁned as the number of
participants recruited and randomised per centre per
month. This was summarised and compared using
median rates and the IQR due to the skewness of the
distribution of the data.18 For secondary outcomes, the
percentage of eligible patients randomised and rando-
mised patients assessed and analysed with the primary
outcome (retention), were expressed in terms of the
median and IQR. Comparisons were made between
categories of different characteristics using appropriate
non-parametric tests; Wilcoxon rank sum (for
characteristics with two levels), Kruskal-Wallis (three or
more nominal levels) and non-parametric test of trend
(three or more ordered levels)19). Additionally, associa-
tions between trial characteristics and recruitment
rates were investigated individually using Wilcoxon
rank sum tests to compare trials on the presence and
absence of certain characteristics. Analysis was carried
out on a complete case basis so where the characteris-
tic information, the recruitment or retention data were
missing these were excluded. Data were collected in
excel and transferred to the R statistical software for
analysis.20
The recruitment period was calculated as the time
between dates of recruitment start and recruitment com-
pletion. If only months were reported the recruitment
period was estimated as the time between the 1st of the
ﬁrst month and the end of the ﬁnal month unless expli-
citly stated otherwise. If the date of the ﬁrst recruit was
reported instead of the date of start of recruitment then
the 1st of the month of the ﬁrst recruit was taken as the
start of recruitment. Start of screening was used to calcu-
late the recruitment period where the start of recruit-
ment was not reported. In cases where information on
the start and end of the recruitment period was not
explicitly reported this was estimated from subtracting
the length of the follow-up period from the length of
study period where this was suitably reported.
The recruitment rate was calculated in two distinct
ways. First, to calculate the overall recruitment rate, the
total number of patients recruited was divided by the
maximum number of sites recruiting, then divided by
total number of months that the trial recruited for. In
reality the opening of trial sites is likely to be staggered.
For the majority of trials most sites do not recruit for the
entire recruitment period. For this reason this estimate
of the overall recruitment rate for multicentre trials is
likely to be an underestimate. To account for the differ-
ences in start-up times for sites and the corresponding
site-speciﬁc recruitment periods, where available, the
centre-speciﬁc recruitment periods were extracted.
These were averaged over the number of sites to give an
average centre-speciﬁc recruitment period. An average
recruitment rate was calculated as the total number of
patients recruited, divided by the maximum number of
sites and then divided by the average number of months
recruiting.
Table 1 Characteristics of the trials included in the review
Characteristic n (%)
Trial design (n=151)
Parallel 129 (85)
Factorial 10 (7)
Crossover 1 (1)
Other (patient preference/Zelen’s) 11 (7)
Arms (n=151)
2 101 (67)
3 30 (21)
4 13 (9)
>4 7 (5)
Clinical area (n=151)
Cancer/oncology 8 (5)
Mental health 27 (18)
Musculoskeletal 19 (13)
Obstetrics and gynaecology 9 (6)
Primary care 7 (5)
Cardiovascular 12 (8)
Gastrointestinal 6 (4)
Respiratory 14 (9)
Stroke 4 (3)
Diabetes 4 (3)
Dermatology (including ulcers) 10 (7)
Other* 31 (21)
Setting (n=151)
Hospital 82 (54)
General practice 20 (13)
Mixed 25 (17)
Community 16 (11)
Other† 8 (5)
Intervention type (n=151)
Drug intervention 37 (25)
Therapy 36 (24)
Surgery 19 (13)
Complex intervention 13 (9)
Other‡ 46 (30)
Control type (n=151)
Placebo 30 (20)
Active 121 (80)
Patient blinded? (n=147)
No 29 (19)
Yes 118 (79)
Centres outside the UK? (n=151)
No 138 (91)
Yes 13 (9)
Geographical spread (n=148)
Multiple regions 119 (80)
Regional 29 (20)
Some form of pilot§?
Yes 59 (41)
No 87 (60)
Not stated 5 (3)
*Alcohol abuse, chronic fatigue, nutrition, infectious diseases,
paediatric (general, dermatology, anaesthesiology), gerontology,
hepatology (hepatitis C), intensive care, multiple sclerosis, minor
surgery, neurology (Bell’s palsy, cerebral palsy epilepsy),
neurosurgery, ophthalmology, otorhinolaryngology, physical
exercise, rehabilitation, resuscitation, sleep disorders, speech
therapy, urology (general, urinary tract infections, incontinence,
prostate disorders), vascular.
†HIV Clinical Centres, University Clinics, Sexual Health Clinics,
Primary and Secondary Strike Care service, Intellectual Disability
Services, Public Schools, Leisure Centres, Physical Therapy
Classes and Specialist care centres.
‡Technique, equipment, diagnostic intervention, advice and
information, consultation, patient pathway, drug versus surgery,
health professional.
§Any mention of pilot work or feasibility study recorded.
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RESULTS
In total 778 reports were published between January
2004 and April 2016 in the HTA Journal and 596 of
these were excluded following screening of all titles and
abstracts. The search produced 191 trial reports of ran-
domised trials of which a further 40 were excluded for
various reasons (18 cluster RCTs; 15 pilot/feasibility
studies; 3 inﬂuenza vaccination trials and four excluded
for other reasons). The 15 pilot/feasibility studies were
standalone/external trials at the outset and were not
deﬁnitive trials that were changed to a pilot study as a
result of poor recruitment. In total, 151 individually
RCTs were included in the review and analysed as shown
in ﬁgure 1.
Trial characteristics
The characteristics of the 151 trials included in the
review are summarised in table 1. The majority of trials
were two armed, parallel group, multicentre trials. Trials
were identiﬁed from a variety of different clinical areas
with 18% (27/151) of trials in mental health, including
neurosciences, psychiatry and psychology, and 13% (19/
151) of trials of musculoskeletal conditions, including
orthopaedics, rheumatology and back pain. Trials were
Table 2 Recruitment and sample size characteristics of the trials included in the review
Characteristic (N=151) n (%) Mean (SD) Median Range
No. of centres
1 8 (5) 29 (35) 15 1–274
2–5 23 (15)
6–10 21 (14)
11–20 33 (22)
21–50 35 (23)
51–100 22 (15)
>100 5 (3)
Missing 4 (3)
Original target recruitment
≤200 14 (9) 1231 (2946) 545 90–28 000
201–400 40 (26)
401–600 31 (21)
601–800 15 (10)
>800 50 (33)
Missing 1 (1)
Final target recruitment
≤200 17 (11) 1132 (2926) 480 44–28 000
201–400 49 (32)
401–600 27 (18)
601–800 13 (9)
>800 45 (30)
Final total recruitment
≤200 24 (16) 1014 (2673) 424 19–24 510
201–400 48 (32)
401–600 28 (19)
601–800 12 (8)
>800 39 (26)
Final recruitment target achieved
Yes 85 (56)
No, but with 80% of target 119 (79)
No, <80% of target 32 (21)
Timing of primary outcome follow-up (months postrandomisation)
<1 month 27 (18) 9 (10) 6 0–48
1–6 months 54 (36)
6–18 months 36 (24)
>18 months 21 (14)
Missing 13 (9)
Timing of final follow-up (months postrandomisation)
<1 month 9 (6) 15 (18) 12 0.066–120
1–6 months 20 (13)
6–18 months 84 (56)
>18 months 33 (22)
Missing 5 (3)
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most commonly set in hospitals (54% (82/151)) and
91% (137/151) took place solely in the UK. Drug trials
were as common as therapy trials, both occurred more
frequently than surgery trials. 30% (46/151) of trials
used an intervention that was not easily categorised and
there was a far greater number of trials that used an
active control (80% (121/151)) compared with a
placebo (20% (30/151)).
The trial characteristics relating to recruitment and
sample size are summarised in table 2. The ﬁnal recruit-
ment/sample size target ranged from 44 participants to
28 000 and ﬁnal total actual/achieved recruitment ranged
from 19 participants to 24 510. Two trials targeted and
achieved recruitment of 20 000 or more participants; one
of these was a trial of trauma patients21 and the other was a
cervical screening trial.22 Overall 56% (85/151) of
trials recruited to their ﬁnal recruitment target and 79%
(119/151) managed to recruit to within 80% of the recruit-
ment target. For 34% (52/151) of trials the original sample
size target was revised (downward in 79% (41/52)). Eight
single-centre trials were identiﬁed. Five trials recruited in
more than 100 centres; the maximum number of centres
was 274. The majority of trials had a ﬁnal follow-up visit at
18 months or less postrandomisation and the longest
reported ﬁnal follow-up was 10 years postrandomisation.
CONSORT and recruitment data
The data completeness in relation to CONSORT and
recruitment information is summarised in table 3. Out
of the 151 trials identiﬁed 95 (63%) demonstrated com-
plete compliance with the CONSORT statement and
reported each of the number: screened, eligible,
declined consent, recruited and assessed in their
primary outcome. The number of participants recruited,
randomised and assessed for the primary outcome, used
to measure retention, was available for all 151 trials. To
calculate the recruitment rate 144 out of 151 trials
reported the maximum length of the recruitment
period, from ﬁrst centre opening to completion of
recruitment, and 106 reported the total number of
centres that recruited at least one participant.
Centre-speciﬁc recruitment information, used to calcu-
late an average recruitment period per centre, could
only be extracted from 34 of the 111 trials (25%). The
overall recruitment rate, based on the maximum recruit-
ment length, was calculated for 142 out of 151 RCTs.
Recruitment and retention rates
From the 142/151 (94%) trials with sufﬁcient
information the median recruitment rate was found to
Table 3 Data completeness in relation to CONSORT
guidelines and recruitment information
Trial characteristic (N=151) n (%)
Number screened 127 (84)
Number eligible 109 (72)
Number refused/declined consent 106 (70)
Total recruitment 151 (100)
Number included in primary analysis
(retention)
151 (100)
Number of centres 106 (70)
Maximum recruitment length 144 (95)
Centre-specific recruitment length 34 (23)
Recruitment rate can be calculated 142 (94)
CONSORT, Consolidated Standards of Reporting Trials.
Figure 2 Recruitment Rates by clinical area for the 151 Health Technology Assessment trials considered.
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be 0.92 patients recruited per centre per month. This
ranged from 0.04 to 57.75 patients per centre per
month, with 80th and 90th percentiles of 4.4 and 10.1
patients recruited per centre per month, respectively.
The two studies found to have the largest recruitment
rates were single-centre studies,23 24 recruited from
obstetrics and gynaecological populations (ﬁgure 2).
The eight single-centre studies produced ﬁve of the
nine23–31 largest recruitment rates ranging from 16 to 58
patients per centre per month. Taking the multicentre
studies on their own the median recruitment was 0.86
patients recruited per centre per month with a range
from 0.04 to 30.11 patients recruited per centre per
month. A median of 70% (IQR 51–87%) of eligible
patients were consented and randomised and a median
89% (IQR 79–97%) of randomised patients had valid
primary outcome data for analysis (table 4).
Tables 5 and 6 summarise the trial recruitment and
retention rates by various trial characteristics (setting,
number of arms, control type, original and ﬁnal recruit-
ment targets, total number recruited and time of
follow-up). There is some statistical evidence of an asso-
ciation between trial setting, ﬁnal recruitment target
and the total number recruited although there is no
clear pattern to these associations.
Table 7 compares the results of the current review, in
terms of successful recruitment to target sample size,
with two previous reviews.3 4 It should be noted that
there is some overlap in the trials included in our review
and Sully et al; so we have included a column with the
non-overlapping time interval for the 2009–2016 data.
Table 7 shows that reaching 100% of the original sample
size target is lower in 2009–2016 than previous periods/
reviews; with only 50% (45/90) achieving the original
sample size target. The original sample size target was
revised in 39% (35/90) of trials; and this revision was
downwards for the majority of trials, 71% (25/35).
DISCUSSION AND CONCLUSIONS
This study provides a comprehensive review of the
recruitment and retention data of a cohort of 151 RCTs
funded and published by the UK NIHR HTA
Programme from 2004 to 2016. This review found that
the ﬁnal recruitment target sample size was achieved
in 56% (85/151) of the RCTs; the median recruitment
rate (participants per centre per month) was 0.92
(IQR 0.43–2.79) and the median retention rate 89%
(IQR 79–97%).
This review found that 56% of publicly funded RCTs
achieve their target sample size, a similar ﬁgure to that
found in the most recent review of 55%, by Sully et al
which covered the period of 2002 to 2008.4 However,
there is still a suggestion that recruitment success is
improving slightly compared with the previous review
covering the period of 1994 to 2002.3 Even though the
recruitment picture is improving there is certainly still
room for improvement with more than half of the 151
Table 5 Association between recruitment rate (number of
patients/centre/month) and trial characteristics
Characteristic n Median IQR p Value
Setting
Hospital 82 1.22 0.58–2.61
General practice 20 0.52 0.23–0.85
Mixed 25 0.98 0.46–3.57
Community 16 1.62 0.38–4 0.043*†
Other 8 3.62 0.53–11.48
Arms
2 101 0.98 0.44–3.01
3 30 0.89 0.39–5.86
4 13 1.04 0.76–2.45
>4 7 0.61 0.39–2.43 0.889†
Control type
Placebo 30 1.29 0.54–4.01
Active 121 0.88 0.42–2.6 0.427‡
Original target recruitment
≤200 14 0.49 0.21–2.23
201–400 40 1.30 0.51–2.26
401–600 31 0.87 0.42–2.33 0.033§
601–800 15 0.87 0.39–2.61
>800 50 1.34 0.58–5.73
Final target recruitment
≤200 17 0.87 0.59–3.5
201–400 49 1.96 0.72–5.68
401–600 27 0.72 0.42–1.67
601–800 13 0.41 0.07–1.14 <0.001§
>800 45 0.89 0.39–4.42
Total recruitment
≤200 24 0.60 0.34–1.72
201–400 48 1.40 0.42–4.28 <0.001§
401–600 28 0.84 0.39–1.61
601–800 12 1.51 0.28–2.17
>800 39 1.38 0.43–5.48
Timing of final follow-up
<1 month 9 1.77 0.39–7.48
1–6 months 41 1.11 0.73–5.43 0.352§
6–18 months 63 0.62 0.31–1.98
>18 months 33 0.87 0.42–3.85
*The category ‘other’ was not included in Kruskal-Wallis test.
†p Values are reported from a Kruskal-Wallis test.
‡p Values are reported from a Wilcoxon rank sum test.
§p Values are reported from a nonparametric test of trend
(Cuzick).
Table 4 Overall recruitment and retention rates
Median IQR Range
Eligible patients
consented and
randomised (N=109)
70% 51–87% 14–100%
Recruited per centre
per month (N=142)
0.92 0.43–2.79 0.04–57.75
Randomised patients
retained and assessed
in primary outcome
(N=151)
89% 79–97% 23–100%
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publicly funded RCTs not recruiting to target which in
some cases was revised down during the course of the
trial. These ﬁndings are congruent with the concerns of
clinical trials unit directors.11
There is a possible relationship between planned
sample size and recruitment rate with recruitment rate
increasing as the target sample size increases. Sample
sizes are inﬂated for expected attrition or non-response
and this is commonly set at 10–20%.18 32 The estimate
of average retention was 89% suggesting that the current
inﬂation of sample sizes for attrition is reasonable.
Overall retention is not as big an issue as recruitment in
terms of fulﬁlling a sample size for a primary outcome.
These ﬁndings slightly contrast with the concerns of
clinical trials unit directors’.11 The retention ﬁgure,
however, will be affected by the number of trials with
short-term outcomes and the use of survival analysis
methods with time to event outcomes, where missing
outcomes are typically censored at the time of any loss
to follow-up and but included in the analysis.
This study has several limitations. Data extraction was
carried out by two independent reviewers. Reviewers
conferred to try to ensure consistency in the interpret-
ation of data extraction items; but it is possible that
errors have occurred. Crude recruitment rates, assuming
all centres were recruiting for the same time period
were calculated; as such the recruitment rate estimates
may be an underestimation of the true recruitment rate.
The study was restricted to publicly funded RCTs pub-
lished as reports in the HTA Journal and not commer-
cially sponsored trials. There is a possibility of
publication bias as this study is restricted to trials that
have had their results published in the NIHR HTA
Journal; as not all funded trials are actually published.
However the possibility of publication bias is small as a
review of projects funded by the NIHR HTA
Programme, between 2002 and 2011, found that 98%
(274/280) published in the programme’s journal.33 The
HTA’s expectation (in line with their contract) is that all
HTA Programme funded studies publish in the NIHR
Journals Library, even when they have had to close early
because of, for example, poor recruitment. The HTA
Table 7 Comparison of current review with results of two previous reviews in terms of successful recruitment to target
sample size and extensions to recruitment
Review McDonald et al3 Sully et al4 This study This study
Recruitment period 1994–2002 2002–2008 2009–2016 2004–2016
Number of trials in the study N=122 N=73 N=90 N=151
Recruited 100% of original target 38 of 122 (31%) 40 of 73 (55%) 45 of 90 (50%) 61 of 151 (40%)
Original target was revised 42 of 122 (34%) 14 of 73 (19%) 35 of 90 (39%) 52 of 151 (34%)
Original target revised upward 6 of 42 (14%) 5 of 14 (36%) 10 of 35 (29%) 11 of 52 (21%)
Original target revised downward 36 of 42 (86%) 9 of 14 (64%) 25 of 35 (71%) 41 of 52 (79%)
Recruited 80% of original target 67 of 122 (55%) 57 of 73 (78%) 65 of 90 (72%) 95 of 151 (63%)
Recruited 100% of revised target 19 of 42 (45%) 10 of 14 (71%) 26 of 35 (74%) 28 of 52 (54%)
Recruited 80% of revised target 34 of 42 (80%) 13 of 14 (93%) 31 of 35 (89%) 48 of 52 (92%)
Extended their recruitment 65 of 122 (54%) 33 of 73 (45%) 28 of 90 (31%) 49 of 151 (32%)
Table 6 Association between the trial retention rate (% of
randomised participants with valid primary outcome data
for analysis) and trial characteristics
Characteristic n Median IQR p Value
Setting
Hospital 81 92.4 81.7–99.1
General
practice
20 85.6 77.4–91.0
Mixed 25 90.0 84.8–97.4
Community 16 85.4 79.1–96.1 0.019*†
Other 8 99.4 98.8–
100.0
Arms
2 100 0.90 0.82–0.98
3 30 0.89 0.79–0.97
4+ 20 0.92 0.83–0.97 0.747†
Control type
Placebo 30 90.0 88.7–99.4
Active 120 89.9 81.0–97.4 0.166‡
Final target recruitment
≤200 17 93.7 87.6–98.3
201–400 49 89.2 79.8–96.8 <0.001§
401–600 27 86.7 72.2–
100.0
601–800 13 86.3 83.2–89.9
>800 44 94.0 76.4, 99.4
Total recruitment
≤200 23 94.7 86.4–
100.0
201–400 48 89.1 79.3–96.4 <0.001§
401–600 28 85.7 81.7–92.5
601–800 12 89.9 88.5–94.6
>800 39 94.0 77.8–99.3
Timing of final follow-up
<1 month 9 99.3 77.4–
100.0
1–6 months 41 94.6 84.8–
100.0
0.693§
6–18 months 62 86.2 75.1–96.8
>18 months 33 89.2 85.6–95.4
*The category ‘other’ was not included in Kruskal-Wallis test.
†p Values are reported from a Kruskal-Wallis test.
‡p Values are reported from a Wilcoxon rank sum test.
§p Values are reported from a nonparametric test of trend
(Cuzick).
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will ask investigators to include a section/chapter on the
challenges faced and lessons learnt that will then inform
other researchers who might be considering similar
research.
There are limitations in drawing conclusions from this
data, not least in the accuracy of the recruitment rates
calculated, potential confounders not accounted for and
in some cases underlying factors that cannot be mea-
sured in the data. Recruitment to trials is complex and
the complete picture cannot be untangled in a simple
review. This review does, however, provide some pointers
to factors that might need to be considered when esti-
mating recruitment periods for RCTs and could be used
in models of recruitment projection. Recent qualitative
research has also highlighted that realistic estimation of
recruitment rates is complex and that early planning
and pilot and feasibility work to help project trial
recruitment is important.34
In practice, recruitment rates will vary, depending on
whether the target population is acute, where opportun-
istic recruitment will target incident cases, or chronic,
where database recruitment can effectively target preva-
lent cases.34 35 It will also vary according to whether the
intervention is therapeutic or preventive36 and the base
incidence and prevalence rate of the condition.
Based on this review for most publicly funded trials
the recruitment rate is likely to be between 1 and 2 par-
ticipants per centre per week (4–10 a month). There is
considerable variation in the consent, recruitment and
retention rates in publicly funded RCTs. Investigators
should bear this in mind at the planning stage of their
study and not be overly optimistic about their recruit-
ment projections.
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